{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:56:38Z","timestamp":1791860198418,"version":"4.3.4"},"reference-count":77,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain (KD) mutation testing have a well consolidated role in the routine management of chronic myeloid leukemia (CML) patients, as they provide precious information for therapeutic decision-making. Molecular response levels are used to define whether a patient has an \u201coptimal\u201d, \u201cwarning\u201d, or \u201cfailure\u201d response to tyrosine kinase inhibitor (TKI) therapy. Mutation status may be useful to decide whether TKI therapy should be changed and which alternative TKI (or TKIs) are most likely to be effective. Real-time quantitative polymerase chain reaction (RQ-qPCR) and Sanger sequencing are currently the gold standard for molecular response monitoring and mutation testing, respectively. However, in recent years, novel technologies such as digital PCR (dPCR) and next-generation sequencing (NGS) have been evaluated. Here, we critically describe the main features of these old and novel technologies, provide an overview of the recently published studies assessing the potential clinical value of dPCR and NGS, and discuss how the state of the art might evolve in the next years.<\/jats:p>","DOI":"10.3390\/jcm9123865","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T03:51:16Z","timestamp":1606535476000},"page":"3865","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?"],"prefix":"10.3390","volume":"9","author":[{"given":"Simona","family":"Soverini","sequence":"first","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Hematology\/Oncology \u201cLorenzo e Ariosto Ser\u00e0gnoli\u201d, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-2624","authenticated-orcid":false,"given":"Simona","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy"},{"name":"Centro di Ricerca Emato-Oncologica AIL (CREA), ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Hematology Unit, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: The paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","volume":"348","author":"Guilhot","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/bloodadvances.2019000865","article-title":"Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP","volume":"3","author":"Baccarani","year":"2019","journal-title":"Blood Adv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-019-0815-5","article-title":"Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: A position paper","volume":"12","author":"Soverini","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-1-4939-9833-3_12","article-title":"Molecular Monitoring of Chronic Myeloid Leukemia","volume":"2065","author":"Dominy","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3389\/fonc.2019.00833","article-title":"Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches","volume":"9","author":"Izzo","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kitamura, H., Tabe, Y., Ai, T., Tsuchiya, K., Yuri, M., Misawa, S., Horii, T., Kawaguchi, A., Ohsaka, A., and Kimura, S. (2019). A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0207170"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1186\/s40064-016-2258-6","article-title":"Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale","volume":"5","author":"Yoshida","year":"2016","journal-title":"Springerplus"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.2147\/CMAR.S232752","article-title":"Monitoring of minimal residual disease (Mrd) in chronic myeloid leukemia: Recent advances","volume":"12","author":"Cumbo","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cilloni, D., Petiti, J., Rosso, V., Andreani, G., Dragani, M., Fava, C., and Saglio, G. (2019). Digital PCR in myeloid malignancies: Ready to replace quantitative PCR?. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092249"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jmoldx.2019.08.007","article-title":"Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia","volume":"22","author":"Franke","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Coccaro, N., Tota, G., Anelli, L., Zagaria, A., Specchia, G., and Albano, F. (2020). Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093141"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-4939-3360-0_5","article-title":"Digital PCR: Principles and applications","volume":"Volume 1392","year":"2016","journal-title":"Methods in Molecular Biology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Quan, P.-L., Sauzade, M., and Brouzes, E. (2018). dPCR: A Technology Review. Sensors, 18.","DOI":"10.3390\/s18041271"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fphar.2016.00363","article-title":"The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia","volume":"7","author":"Guerrini","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/ijlh.12404","article-title":"Real-Time PCR and Droplet Digital PCR: Two techniques for detection of the JAK2V617F mutation in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"37","author":"Fontanelli","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1080\/10428194.2019.1607325","article-title":"Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia","volume":"60","author":"Santoro","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.14616","article-title":"Comparative analysis between RQ-PCR and digital droplet PCR of BCL2\/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma","volume":"177","author":"Cavalli","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1080\/10428194.2019.1590569","article-title":"Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: A landmark analysis","volume":"60","author":"Berdeja","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3109\/10428194.2011.555569","article-title":"Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay","volume":"52","author":"Goh","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/ejh.13084","article-title":"Droplet digital PCR for BCR\/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression","volume":"101","author":"Wang","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_27","first-page":"1","article-title":"One more stem cell niche: How the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a \u201chypoxic\u201d environment","volume":"214","author":"Rovida","year":"2014","journal-title":"Hypoxia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/gcc.21989","article-title":"Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia","volume":"51","author":"Krumbholz","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1111\/jcmm.14321","article-title":"Large amplicon droplet digital PCR for DNA-based monitoring of pediatric chronic myeloid leukaemia","volume":"23","author":"Krumbholz","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00216-015-9204-2","article-title":"Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR","volume":"408","author":"Lund","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.18632\/oncotarget.23971","article-title":"Genomic BCR-ABL1 breakpoint characterization by a multistrategy approach for \u201cpersonalized monitoring\u201d of residual disease in chronic myeloid leukemia patients","volume":"9","author":"Cumbo","year":"2018","journal-title":"Oncotarget"},{"key":"ref_32","first-page":"2133","article-title":"Feasibility of tumor-derived exosome enrichment in the onco-hematology leukemic model of chronic myeloid leukemia","volume":"44","author":"Bernardi","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1159\/000505088","article-title":"Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message?","volume":"143","author":"Bernardi","year":"2020","journal-title":"Acta Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/jcmm.12873","article-title":"Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor","volume":"20","author":"Corrado","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2155-9929.1000330","article-title":"Digital PCR (Dpcr) a Step Forward to Detection and Quantification of Minimal Residual Disease (MRD) in Ph+\/BCR-ABL1 Chronic Myeloid Leukemia (CML)","volume":"8","author":"Bernardi","year":"2017","journal-title":"J. Mol. Biomark. Diagn."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/cam4.2087","article-title":"Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation","volume":"8","author":"Bernardi","year":"2019","journal-title":"Cancer Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","article-title":"Evaluation of residual disease and TKI duration are predictive factors for molecular recurrence after stopping Imatinib first-line in chronic phase CML Patients","volume":"25","author":"Nicolini","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1182\/blood-2018-99-120363","article-title":"Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Level. Comparison of Qpcr, d-PCR and CD26 Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR)","volume":"132","author":"Abruzzese","year":"2018","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-55872-7","article-title":"Precision cancer monitoring using a novel, fully integrated, microfluidic array partitioning digital PCR platform","volume":"9","author":"Dueck","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ejh.13238","article-title":"Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay","volume":"103","author":"Kjaer","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ejh.13282","article-title":"\u201cVariant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.\u201d Is dPCR the key?","volume":"103","author":"Bernardi","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3343\/alm.2020.40.1.72","article-title":"Performance evaluation of the QXdX BCR-ABL %Is droplet digital PCR assay","volume":"40","author":"Chung","year":"2020","journal-title":"Ann. Lab. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jmoldx.2018.08.012","article-title":"Optimized Digital Droplet PCR for BCR-ABL","volume":"21","author":"Maier","year":"2019","journal-title":"J. Mol. Diagn."},{"key":"ref_45","first-page":"2867","article-title":"Standardization of Two Dpcr Platforms for Detection of BCR\/ABL1\u2014Minimal Residual Disease (MRD) in Ph+ Chronic Myeloid Leukemia (CML)","volume":"130","author":"Fava","year":"2017","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2019-131207","article-title":"Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia","volume":"134","author":"Asghari","year":"2019","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jmoldx.2019.03.002","article-title":"Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA","volume":"21","author":"Brown","year":"2019","journal-title":"J. Mol. Diagn."},{"key":"ref_48","unstructured":"Scott, S., Cartwright, A., Tapley, A., Boeckx, N., Cayuela, J.M., Corner, A., Dulucq, S., Galimberti, S., Lauricella, C., and Rose, S. (2020). Digital PCR For The Measurement of BCR-ABL1 In CML: A New Dawn?. EHA Library, 294652."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Spiess, B., Rinaldetti, S., Naumann, N., Galuschek, N., Kossak-Roth, U., Wuchter, P., Tarnopolscaia, I., Rose, D., Voskanyan, A., and Fabarius, A. (2019). Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214305"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1159\/000510440","article-title":"RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients?","volume":"13","author":"Zanaglio","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1038\/bcj.2015.75","article-title":"Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment","volume":"5","author":"Russo","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","article-title":"Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase","volume":"141","author":"Kulvait","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3324\/haematol.2016.145888","article-title":"Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia","volume":"101","author":"Baer","year":"2016","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Soverini, S., de Benedittis, C., Castagnetti, F., Gugliotta, G., Mancini, M., Bavaro, L., Machova Polakova, K., Linhartova, J., Iurlo, A., and Russo, D. (2016). In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2635-0"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","article-title":"Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain","volume":"122","author":"Soverini","year":"2013","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"21982","DOI":"10.18632\/oncotarget.8010","article-title":"Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients","volume":"7","author":"Soverini","year":"2016","journal-title":"Oncotarget"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(19)30027-4","article-title":"Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: A population-based study","volume":"6","author":"Kizilors","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: The NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bulcan.2019.05.011","article-title":"Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia","volume":"107","author":"Cayuela","year":"2020","journal-title":"Bull. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1158\/1078-0432.CCR-18-0167","article-title":"Single-molecule sequencing reveals patterns of preexisting drug resistance that suggest treatment strategies in Philadelphia-positive leukemias","volume":"24","author":"Schmitt","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.yexmp.2017.06.007","article-title":"Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology","volume":"103","author":"Minervini","year":"2017","journal-title":"Exp. Mol. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Petiti, J., Rosso, V., Croce, E., Franceschi, V., Andreani, G., Dragani, M., de Gobbi, M., Lunghi, M., Saglio, G., and Fava, C. (2020). Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010271"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Grassi, S., Guerrini, F., Ciabatti, E., Puccetti, R., Salehzadeh, S., Metelli, M.R., Di Vita, A., Domenichini, C., Caracciolo, F., and Orciuolo, E. (2020). Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients. Cancers, 12.","DOI":"10.3390\/cancers12071738"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2017.186528","article-title":"Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenstr\u00f6m macroglobulinemia","volume":"103","author":"Drandi","year":"2018","journal-title":"Haematologica"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-72834-6","article-title":"Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients","volume":"10","author":"Zocco","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.leukres.2018.04.013","article-title":"Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia","volume":"69","author":"Tan","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.exphem.2020.01.001","article-title":"Detection of T315I using digital polymerase chain reaction in allogeneic transplant recipients with Ph-positive acute lymphoblastic anemia in the dasatinib era","volume":"81","author":"Akahoshi","year":"2020","journal-title":"Exp. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2019-126767","article-title":"Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making","volume":"134","author":"Soverini","year":"2019","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2019-123409","article-title":"Droplet Digital PCR Phasing (DROP-PHASE): A Novel Method for Straightforward Detection of BCR-ABL1 Compound Mutations in Tyrosine Kinase Inhibitors Resistant Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL)","volume":"134","author":"Vannuffel","year":"2019","journal-title":"Blood"},{"key":"ref_71","unstructured":"Galimberti, S., Guerrini, F., Grassi, S., Bocchia, M., Bavaro, L., Ciabatti, E., Dragani, M., Gottardi, E.M., Izzo, B., and Lunghi, F. (2020). Digital Droplet PCR is a fast and effective tool for detecting T315I mutation in Chronic Myeloid Leukemia. EHA Library, 294653."},{"key":"ref_72","first-page":"4176","article-title":"An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease","volume":"130","author":"Daraio","year":"2017","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5045\/br.2018.53.1.3","article-title":"The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era","volume":"53","author":"Morello","year":"2018","journal-title":"Blood Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia","volume":"23","author":"Giustacchini","year":"2017","journal-title":"Nat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.saa.2012.10.066","article-title":"Study of polymorphism in imatinib mesylate: A quantum chemical approach using electronic and vibrational spectra","volume":"103","author":"Srivastava","year":"2013","journal-title":"Spectrochim. Acta Part A Mol. Biomol. Spectrosc."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/12\/3865\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:38:37Z","timestamp":1760179117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/12\/3865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":77,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["jcm9123865"],"URL":"https:\/\/doi.org\/10.3390\/jcm9123865","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,27]]}}}